Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna¿s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases.
| Last: | $8.1684 |
|---|---|
| Change Percent: | 3.53% |
| Open: | $8 |
| Close: | $7.89 |
| High: | $8.275 |
| Low: | $7.82 |
| Volume: | 223,736 |
| Last Trade Date Time: | 02/27/2026 12:43:12 pm |
| Market Cap: | $448,450,247 |
|---|---|
| Float: | 32,219,865 |
| Insiders Ownership: | 0.32% |
| Institutions: | 24 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.kyvernatx.com |
| Country: | US |
| City: | Emeryville |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Kyverna Therapeutics Inc. (NASDAQ: KYTX).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
